Upgrade to SI Premium - Free Trial

Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Stifel

July 20, 2026 4:25 PM
Stifel analyst Paul Matteis raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $25.00 (from $24.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change